메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

BioDlink Completes First International Shipment of Bevacizumab to Colombia

Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death in Colombia[1]. This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its antibody commercialization platform, as well as robust production quality and supply chain management systems. SUZHOU, China, Oct. 27, 2025 -- BioDlink announced the first international shipment of its bevacizumab injection biosimilar to Colombia in partnership with Kexing BioPharm. Bo
- 김갑성 기자
- 2025-10-27 20:30
National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability

SANTIAGO, Chile, Oct. 27, 2025 -- The highly anticipated 2025 IDF World Dairy Summit took place from October 20 to 23 in Santiago, Chile. Drawing global attention, the event served as an important barometer for the future of the dairy industry. Liu Chunxi, Chairman of the National Center of Technology Innovation for Dairy (NCTID) and Senior Executive President of Yili Group, was invited to the meeting of the IDF Task Force on the Paris Dairy Declaration on Sustainability, where he joined global dairy leaders, experts, and scholars in discussions on the industry's sustainable developmen
- 김갑성 기자
- 2025-10-27 19:23
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner

SYDNEY, Oct. 27, 2025 -- Kazia Therapeutics Limited ("Kazia" or the "Company") today announced its intention to request and hold a follow-up Type C meeting with the U.S. Food & Drug Administration (FDA) to discuss overall survival (OS) findings in newly diagnosed glioblastoma (GBM) patients treated with paxalisib and to seek agency feedback on a potential regulatory pathway aligned with the FDA Oncology Center of Excellence's Project FrontRunner initiative. "GBM remains one of the most lethal cancers with limited therapeutic options. In line with the FDA On
- 김갑성 기자
- 2025-10-27 19:15
China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392)

Designation granted for gotistobart (BNT316/ONC392) for the treatment of patients with squamous non-small cell lung cancer (sqNSCLC), an aggressive subtype of lung cancer Breakthrough Therapy designation will allow for an expedited development and regulatory review of gotistobart in China Global pivotal PRESERVE-003 Phase 3 clinical trial in squamous non-small cell lung cancer Is Ongoing ROCKVILLE, Md., Oct. 27, 2025 -- OncoC4 announced today that China's National Medical Product Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for gotist
- 김갑성 기자
- 2025-10-27 19:00
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial

Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94 patients enrolled out of 102 planned across Korea and the U.S. Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct. 27, 2025 -- Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) announced that its first-in-class idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin (DWN12088) received a recommendation to continue its global Phase 2 clinical trial following a positive safe
- 김갑성 기자
- 2025-10-27 19:00
Ascletis to Present Study Results of ASC30 Oral Tablet, ASC30 Injection, and Combination of ASC31 and ASC47 at ObesityWeek® 2025

[ 메디채널 김갑성 기자 ] -Multiple posters being presented on Ascletis' small molecule and peptide obesity programs -Full analysis of 28-day multiple ascending dose study of oral GLP-1R small molecule agonist ASC30 as a late-breaking poster as well as ASC30 once-monthly treatment formulation and once-quarterly maintenance formulation HONG KONG, Oct. 27, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces multiple poster presentations of its obesity assets including ASC30, and combination of ASC31 and ASC47 at ObesityWeek® 2025 in Atlanta, Georgia. Prese
- 김갑성 기자
- 2025-10-27 18:00
MINISH Technology Has Successfully Concluded Its First U.S. MINISH Veneers Course, Certifying 22 Dentists

SEOUL, South Korea, Oct. 27, 2025 -- Health-tech company MINISH Technology Inc. announced on the 27th that 22 dentists completed its 15th MINISH Course, the first session held for local practitioners in the United States. The three-day course was held from October 24 to 26 at the VITA North America training center in Orange County, California, as an officially recognized Continuing Education (CE) program for dental professionals in the United States. Although tuition fees were nearly 50% higher than comparable local programs, the course sold out quickly, demonstrating strong in
- 김갑성 기자
- 2025-10-27 14:58
Durex Launches "The Pull Out Game Game" to Prove Why Pulling Out is a Game Over Strategy

[ 메디채널 김장윤(JASON KIM) 기자 ] A Hilarious (and Frustrating) Reminder That This Method Doesn't Work. SINGAPORE, Oct. 27, 2025 -- Many men think they've mastered the "pull-out" game—but science says otherwise. In reality, 22 out of 100 people who rely on this outdated method end up with an unintended pregnancy. Durex is here to make sure people don't gamble with their futures—unless it's just for fun. Durex Pullout Game - Launch Video Introducing The Pull Out Game Game, a retro-inspired digital experience that hilariously exposes the flaws of the pull-o
- 김장윤(JASON KIM) 기자
- 2025-10-27 14:23
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials

SINGAPORE, Oct. 27, 2025 -- Raffles Medical Group (the Group) and Gene Solutions have signed a Memorandum of Understanding (MOU) on 22 October 2025 to streamline patient recruitment for oncology clinical trials, marking a significant milestone in advancing precision medicine in Southeast Asia. Under this partnership, the Group and Gene Solutions will collaborate to identify patients eligible for pharma-sponsored clinical trials. Patients undergoing Comprehensive Genomic Profiling (CGP) via Gene Solutions will be automatically screened for eligibility. The Group's Clinical Trials Unit w
- 김갑성 기자
- 2025-10-27 13:22
KLN Named Exclusive Distributor for Siemens Healthineers

[ 메디채널 김갑성 기자 ] Point-of-Care Testing Solutions in Hong Kong HONG KONG, Oct. 27, 2025 -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) announces a strategic partnership between its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), and global medical technology leader Siemens Healthineers AG (Stock Code SHL.DE). KLN Medical will serve as the exclusive distributor for Siemens Healthineers' Point-of-Care Testing products in Hong Kong. This partnership marks a major milestone for KLN Medical as it expands in life sciences sector. KLN Medical will provide end-to
- 김갑성 기자
- 2025-10-27 12:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-03_MON

2025-11-02_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 03일 07시 00분